Coming Soon
ERRα Agonist
Exercise mimetic for endurance support. Join our waitlist to be notified when available.
250mcg
Planned Dosage
ERRα
Target Receptor
Exercise
Mimetic Action
Soon
Coming Soon
Coming Soon
Advanced exercise mimetic peptide therapy designed to support endurance and metabolic health. Be the first to know when it becomes available.
ERRα agonist formulation
Ideal For
Individuals seeking to enhance endurance capacity, optimize metabolic function, and support exercise-related adaptations without conventional training stress.
The Science
SLU-PP-332 is a novel small molecule agonist of estrogen-related receptor alpha (ERRα), a key regulator of cellular energy metabolism and mitochondrial function. This compound represents a breakthrough in exercise mimetic research, capable of activating metabolic pathways typically engaged during endurance training.
ERRα plays a crucial role in controlling genes involved in oxidative metabolism, mitochondrial biogenesis, and energy production. By activating this receptor, SLU-PP-332 may trigger cellular adaptations similar to those induced by sustained aerobic exercise—without the physical stress of training.
Preclinical research has demonstrated SLU-PP-332’s potential to enhance endurance capacity, improve metabolic flexibility, increase mitochondrial density, and support overall metabolic health. This makes it a promising therapeutic option for individuals unable to engage in traditional exercise or seeking to augment their training adaptations.
Join the Waitlist
How It Works
SLU-PP-332 activates ERRα to trigger exercise-like metabolic adaptations at the cellular level.
Selectively activates estrogen-related receptor alpha, a master regulator of energy metabolism that controls genes involved in mitochondrial function and oxidative capacity.
Stimulates the production of new mitochondria and enhances existing mitochondrial function, increasing cellular energy production capacity and metabolic efficiency.
Upregulates oxidative metabolic pathways, improving the body’s ability to utilize fat and oxygen for energy production, mimicking endurance training adaptations.
Potential Benefits
Increases aerobic capacity and endurance performance by activating the same metabolic pathways engaged during sustained aerobic exercise training.
Improves metabolic flexibility and energy utilization, supporting better fat metabolism, glucose regulation, and overall metabolic health.
Promotes mitochondrial biogenesis and enhances mitochondrial efficiency, increasing cellular energy production and reducing oxidative stress.
May support cardiovascular health through improved endothelial function, enhanced cardiac efficiency, and better overall circulatory performance.
Provides exercise-like benefits for individuals unable to engage in traditional training due to injury, disability, or time constraints.
May support healthy aging by preserving metabolic function, maintaining muscle oxidative capacity, and promoting cellular resilience.
Your Journey
Our medical team will guide you through every step once SLU-PP-332 becomes available.
Sign up to be notified when SLU-PP-332 is available and receive early access to this breakthrough therapy.
Comprehensive assessment of your metabolic health, fitness goals, and candidacy for ERRα agonist therapy.
Personalized SLU-PP-332 dosing plan designed for your specific needs, with clear administration guidelines.
Regular follow-up to track metabolic improvements, endurance gains, and optimize your therapeutic outcomes.
Research & Development
SLU-PP-332 represents the cutting edge of metabolic medicine. As an ERRα agonist, it offers a novel approach to enhancing endurance and metabolic health through pharmacological activation of exercise-responsive pathways.
ERRα
Selective agonist of estrogen-related receptor alpha, a key metabolic regulator
Exercise
Mimics exercise-induced metabolic adaptations without conventional training stress
Questions
An exercise mimetic is a compound that activates similar metabolic pathways and produces comparable physiological adaptations to those induced by physical exercise—without requiring actual training. SLU-PP-332 triggers cellular changes typically seen with endurance training by activating ERRα, a key metabolic regulator.
SLU-PP-332 is currently in development and not yet available for patient use. We are closely monitoring research progress and regulatory developments. Join our waitlist to be among the first notified when this therapy becomes available at BHRC.
Estrogen-related receptor alpha (ERRα) is a nuclear receptor that controls genes involved in energy metabolism, mitochondrial function, and oxidative capacity. When activated by SLU-PP-332, ERRα increases mitochondrial biogenesis, enhances fat oxidation, and improves metabolic efficiency—similar to endurance exercise training.
Potential candidates include individuals unable to exercise due to injury or disability, those seeking to enhance endurance performance, people with metabolic dysfunction, and anyone interested in optimizing mitochondrial health and metabolic function. Medical evaluation will determine candidacy once available.
While SLU-PP-332 mimics certain metabolic adaptations of exercise, it does not replace all benefits of physical activity, such as mechanical stress on bones and muscles, neuromuscular coordination, or psychological benefits. It’s best viewed as a complement to exercise or an alternative for those unable to train conventionally.
Preclinical studies have demonstrated SLU-PP-332’s ability to increase endurance capacity, improve metabolic parameters, and enhance mitochondrial function. Research is ongoing to establish safety, efficacy, and optimal dosing protocols for human use.
Simply fill out the waitlist form below with your contact information and areas of interest. We’ll notify you as soon as SLU-PP-332 becomes available and provide information about scheduling an initial consultation with our medical team.
Join the Waitlist
Sign up to receive exclusive updates when SLU-PP-332 becomes available and get priority access to this breakthrough therapy.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. SLU-PP-332 is currently in development and not yet available for patient use. This page is for informational purposes only. When available, SLU-PP-332 will be a compounded medication available by prescription only. Not all patients will qualify for therapy, and individual results may vary. A comprehensive medical evaluation will be required to determine candidacy. All claims are based on preclinical research and do not guarantee results in human subjects.
